Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Impact and Experiences of Using Patient Decisions Aids in Hospital Outpatient Mental Health Settings

4 november 2026 bijgewerkt door: University of Southern Denmark

Impact and Experiences of Using Patient Decisions Aids in Hospital Outpatient Mental Health Settings. A Randomised Controlled Trial With a Qualitative Follow-up on Shared Decision-making in the Danish Mental Healthcare (the DAN-SHARE Study)

The DAN-SHARE study evaluates the use of DECISION HELPER™-based patient decision aids (PtDAs) in mental healthcare by exploring the impact of using a DECISION HELPER™ in-consult PtDA on patient involvement in decision-making. The study compares treatment consultations that use a PtDA with treatment consultations in which SDM is practiced without the use of a PtDA and hypothesises that the use of an in-consult PtDA will increase patient involvement in decision-making. Additionally, the study explores how patients and clinicians in mental healthcare understand and experience SDM and the use of the PtDA as part of the SDM practice in mental healthcare.

Studie Overzicht

Gedetailleerde beschrijving

Shared decision-making (SDM) is a collaborative model for treatment decision-making and is widely regarded as a cornerstone of patient-centered care. In SDM, patients and healthcare professionals jointly review available treatment options and identify the solution that best aligns with the patient's preferences and values. Patient decision aids (PtDAS) that are designed to support SDM by presenting treatment options and helping patients formulate and communicate their preferences, are often a central component of SDM. However, little is known about how healthcare professionals and patients understand and experience the use of patient decision aids in their clinical encounters. In particular, there is a lack of knowledge on the use of patient decision aids within mental healthcare.

This study aims to evaluate the impact of Decision Helper™-based PtDAs, when used in mental healthcare. Decision Helper™-based PtDAS are PtDAS designed by using a generic template known as the DECISION HELPER™. They are mandatory to develop and use as part of the implementation of SDM across all hospitals in the Region of Southern Denmark. However, there is a lack of knowledge of whether these PtDAs enhance SDM practices in psychiatric treatment consultations and supports people using mental health services in achieving greater involvement in treament decision-making.

In the study, patients are randomised to either an intervention group or an active control group. In the intervention group, treatment consultations are conducted using the Decision Helper™-based PtDA, whereas consultations in the control group follow SDM practices without the use of the PtDA. Additionally, the study explores patients' and mental healthcare professionals understanding and experiences the PtDAs as part of their SDM practice.

Studietype

Ingrijpend

Inschrijving (Geschat)

62

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age ≥ 18 years
  • In treatment for a mental health disorder in one of the participating settings of the study

Exclusion Criteria:

  • Unable to understand Danish language
  • Unable to provide verbal and written informed consent
  • Diagnosed with cognitive impairment or dementia

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: SDM practice by using a Decision Helper-based PtDA

Patients assigned to the intervention group will be exposed to a Decision Helper™-based PtDA during consultations in which treatment decisions or related issues are addressed. The Decision Helper™-based PtDAS used in these consultations follows a five-step process based on the core principles of shared decision-making: (1) framing the situation and explaining the purpose of the consultation; (2) clarifying the patient's preferred level of information; (3) exploring what matters most to the patient in the decision-making process; (4) presenting the available treatment options, including their advantages and disadvantages; and (5) asking whether the patient is ready to make a decision regarding their preferred treatment option.

Patients assigned to the control group will not be exposed to the Decision Helper™-based PtDA during treatment consultations in which decisions are made. However, because all healthcare professionals in the participating settings have received training in SDM, the control group constitutes an active control condition, as patients will still be exposed to the general principles of SDM during decision-making consultations.

Actieve vergelijker: SDM without the Decision Helper-based PtDA

Patients assigned to the intervention group will be exposed to a Decision Helper™-based PtDA during consultations in which treatment decisions or related issues are addressed. The Decision Helper™-based PtDAS used in these consultations follows a five-step process based on the core principles of shared decision-making: (1) framing the situation and explaining the purpose of the consultation; (2) clarifying the patient's preferred level of information; (3) exploring what matters most to the patient in the decision-making process; (4) presenting the available treatment options, including their advantages and disadvantages; and (5) asking whether the patient is ready to make a decision regarding their preferred treatment option.

Patients assigned to the control group will not be exposed to the Decision Helper™-based PtDA during treatment consultations in which decisions are made. However, because all healthcare professionals in the participating settings have received training in SDM, the control group constitutes an active control condition, as patients will still be exposed to the general principles of SDM during decision-making consultations.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Patient involvement in decision-making
Tijdsspanne: Throughout study completion, an average of 3 months.

Observed level of patient involvement in decision making according to the OPTION 12 scale.

OPTION 12 measures the level of patient involvement in decision-making by assessing recordings of treatment consultations on a 5-point Likert scale (0 to 4). Raw score rangs from 0 to 48 and is converted to a score ranging from 0 to 100. Higher scores indicate a higher level of patient involvement.

Throughout study completion, an average of 3 months.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Patient-perceived level of involvement in decision-making
Tijdsspanne: Patient-assessed within two weeks after the treatment consultation.

Patient-reported perceived involvement in decision-making, measured using the 9-item Shared Decision Making Questionnaire (SDM-Q-9). The SDM-Q-9 assesses the extent to which patients perceive themselves as being involved in decision-making. Patients rate their level of agreement with each of the 9 statements on a 6-point Likert scale. Raw scores range from 0 to 45 and are converted to a standardized score ranging from 0 to 100.

Patient-assessed within two weeks after the treatment consultation.
Clinician-perceived level of involving the patient
Tijdsspanne: Clinician-assessed within two weeks after the treatment consultation.

Clinician-reported perceived level of patient involvement in decision-making, measured using the clinician version of the 9-item Shared Decision Making Questionnaire (SDM-Q-Doc). The SDM-Q-Doc assesses the extent to which clinicians perceive that they involve patients in the decision-making process. Clinicians evaluate each of the 9 items on a 6-point Likert scale. Raw scores range from 0 to 45 and are converted to scores ranging from 0 to 100. Higher scores indicate greater clinician-perceived involvement of patients in decision-making.

Clinician-assessed within two weeks after the treatment consultation.
Personal recovery
Tijdsspanne: Patient-assessed within two weeks after the treatment consultation.

Patient-reported measure of personal recovery, assessed using the Brief INSPIRE-O. The Brief INSPIRE-O is a 5-item self-rated measure of recovery, i.e., a patient-reported outcome measure (PROM), that assesses personal recovery from the patient's perspective.

Each of the five statements is rated by the patient on a 5-point Likert scale ranging from 0 to 4. Item scores are summed and multiplied by 5 to generate a total score ranging from 0 to 100. Higher scores indicate higher levels of patient-perceived personal recovery.

Patient-assessed within two weeks after the treatment consultation.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 april 2026

Primaire voltooiing (Geschat)

30 juni 2027

Studie voltooiing (Geschat)

29 februari 2028

Studieregistratiedata

Eerst ingediend

1 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

9 juni 2026

Eerst geplaatst (Werkelijk)

10 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren